Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

Ann Hematol. 2000 Apr;79(4):214-6. doi: 10.1007/s002770050581.

Abstract

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders frequently develop in patients with acquired immunodeficiency syndrome (AIDS). The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective. However, we report about two AIDS patients with EBV-associated lymphoproliferative disorders not responding to a standard chemotherapy, who achieved complete tumour regression after virustatic therapy with foscarnet.

Publication types

  • Case Reports

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Adult
  • Antiviral Agents / therapeutic use*
  • Epstein-Barr Virus Infections* / complications*
  • Foscarnet / therapeutic use*
  • Humans
  • Lymphoma, AIDS-Related / drug therapy
  • Lymphoproliferative Disorders / virology*
  • Male
  • Middle Aged

Substances

  • Antiviral Agents
  • Foscarnet